AstraZeneca Joins NYSE With Harmonised Global Listing to Broaden Investor Base
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from AstraZeneca ( (GB:AZN) ).
AstraZeneca has begun trading its ordinary shares on the New York Stock Exchange, aligning them under a harmonised global listing structure alongside existing listings on the London Stock Exchange and Nasdaq Stockholm under the ticker AZN. The move replaces its prior US American Depositary Share listing and shifts trading of its US dollar bonds to the NYSE, broadening access to the world’s largest capital market and aiming to expand its US investor base, which management says will support its growth strategy, fund its ambition to reach $80bn in annual revenue and launch 20 new medicines by 2030, and reinforce its position as a leading global biopharmaceutical player.
More about AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company headquartered in Cambridge, UK, specialising in the discovery, development and commercialisation of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology therapies. Its innovative medicines are sold in more than 125 countries and used by millions of patients worldwide, giving the group a broad international footprint across key therapeutic markets.
Find detailed analytics on AZN stock on TipRanks’ Stock Analysis page.
